Cymene and Metformin treatment effect on biochemical parameters of male NMRI mice fed with high fat diet

Peyman Lotfi1, Parichehreh Yaghmaei1* and Azadeh Ebrahim-Habibi2,3*

Abstract

Background: The increasing prevalence of obesity is considered a serious global health threat. Mainly due to change of diet and reduced physical activity, obesity is an important risk factor for chronic diseases. A higher level of cytokines and a general inflammatory state has also been associated with this condition. With this regard, potential anti-obesity compounds with anti-inflammatory properties could be beneficial in better control of the disease. p-Cymene is a natural aromatic compound that has been shown to have anti-inflammatory properties, while the antidiabetic drug metformin has been observed to be effective as an aid for weight loss. In this study, the effect of these compounds was compared in a high fat diet treated mice model.

Methods: 48 adult NMRI mice were randomly divided into six groups: control group receiving a normal diet, high fat diet (HFD) fed control group, sham group receiving HFD and sunflower seed oil, Experimental group 1 (E1) receiving HFD and 20 mg/kg metformin, Experimental group 2 (E2) receiving 20 mg/kg metformin and 20 mg/kg p-cymene, Experimental group 3 (E3) receiving 20 mg/kg p-cymene. Compounds were administered by intragastric gavage for 45 days.

Results: Non-fasting glucose serum levels, ALT, and ALP of E2 and E3 decreased significantly compared to HFD control group. In the E3 group, AST levels decrease was also significant. In E1, non-fasting glucose and TG serum levels decreased significantly compared to HFD control group. Histological observations on liver tissue showed an increase of lipid droplets in the HFD control group compared with the normal group, while upon treatment with the compounds, lipid droplets decreased and the cells appeared to be more ordered.

Conclusion: p-Cymene has a potential to ameliorate biochemical parameters in high fat diet treated mice, and its concurrent use with metformin was effective.

Keywords: Obesity, p-cymene, Metformin, NMRI mice
Obesity is associated with a chronic inflammatory response, where abnormal adipokine production and activation of pro-inflammatory signaling pathways would result in induction of several biological markers of inflammation [9]. Accordingly, a reduction in body weight is followed by a decrease or even a normalization of these parameters [10, 11]. Reports on animal models support the existence of a link between inflammatory processes and obesity, as well as its comorbidities [12, 13]. In addition to their role in metabolic disorders, fat cells potential role in inflammatory process is relatively recently introduced. Moreover, several findings point to common characteristics between inflammatory and immune cells such as complement activation and pro-inflammatory cytokine production [14]. Similar to macrophages, preadipocytes have the capacity for phagocytosis and have been demonstrated to resemble more to macrophages than adipocytes [15, 16]. These findings are suggestive of the possibility for compounds with anti-inflammatory properties to become potential anti-obesity candidates.

*p*-Cymene (p-isopropyltoluene) is a natural aromatic organic compound [17] used as a flavoring agent and in the production of chemicals [18]. It is an important component of plants belonging to the *Thymus* genus, has a simple structure similar to thymol, and is the biological precursor of carvacrol [19]. As part of volatile oils extracted from plants, cymene has been reported to have anti-bacterial and anti-oxidant properties [19, 20]. Recent studies have demonstrated interesting analgesic and anti-inflammatory effect of *p*-cymene itself [21–23]. With regard to these properties, we aimed at investigating the effect of cymene on mice fed with high-fat diet, which could be considered to be at risk of developing obesity. Cymene effect was compared with metformin. Metformin is a safe glucose-lowering drug which has some other indications such as treating polycystic ovarian syndrome [24], aiding in weight loss [25], and some cases of impaired glucose tolerance [26].

### Experimental design

After accommodation for one week, mice were randomly divided into six groups of eight animals as follows: (1) the normal group that received standard rodent diet without any food restriction; (2) high fat diet control group that received a high fat diet (HFD); (3) sham group that received drug solvent (sunflower seed oil) alongside with HFD; (4) Experimental group 1 that received Fat diet plus 20 mg / kg metformin; (5) Experimental group 2 that received HFD plus 20 mg/kg cymene; (6) Experimental group 3 that received HFD with both metformin and cymene at doses of 20 mg/kg.

The experiment duration was 6 weeks and compounds were given by oral gavage.

HFD was prepared from a mix of 15 g of mouse pellet standard chow, 10 g of roasted ground nut, 10 g of milk chocolate and 5 g of sesame crackers; 20 g roasted sesame was added to ten-fold of these components, which amounts into 18 kJ/g. The high fat diet treated group was also given 240 g creamy biscuits weekly [28].

### Chemicals

*p*-Cymene (99.7 % purity) was purchased from Sigma, USA. Metformin was from Kimi Daru Pharmaceutical Co, Iran. Commercial kits used for determination of blood glucose, cholesterol, triglyceride (TG), HDL-C, LDL-C, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were from Pars Azmoon Company, Iran.

### Measured parameters

At the end of the experiment, body weights of animals were measured; animals were anesthetized by inhalation of mild diethyl ether, and their blood was taken. The blood samples were allowed to clot for 30 min at room temperature and centrifuged at 1000 × g at 37 °C for 10 min to separate the serum. Levels of non-fasting glucose, cholesterol, TG, HDL-C, LDL-C, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were determined.

### Statistical analysis

Results are expressed as mean ± S.E.M. Statistical analysis was performed using one-way ANOVA test followed by a Tukey posthoc test. *p* < 0.05 was considered statistically significant.

### Results

#### Body weight

After the end of the experiment, group 1–6 weights were measured. As shown in Table 1, no significant difference was observed in this regard between different groups.
Non-fasting blood glucose
Non-fasting Blood glucose increased significantly upon taking HFD as well as in sham groups, compared to the control group \((p < 0.05)\). Treatment with \(p\)-cymene alone, metformin alone and metformin/cymene complex resulted in significantly decreased levels of blood glucose as compared with the control group, with \((p < 0.001)\), \((p < 0.01)\) and \((p < 0.05)\) respectively (Table 1).

Lipids
Cholesterol levels of the untreated group taking HFD, as well as the sham one were higher than the control group (although not significantly) (Table 1). Between treated groups, giving metformin alone had a better lowering effect on cholesterol (but not significantly). TG levels, which were increased to some extent upon consumption of HFD as well as in the sham group, were significantly decreased upon metformin treatment \((p < 0.05)\), while other treatments, although effective, could not significantly influence TG levels (Table 1).

ALT and ALP
Serum ALT and ALP levels of HFD-given and sham groups were higher than those in the control group. Upon both treatments, a significant lowering of ALT

---

**Table 1** Effects of Metformin and Cymene treatment on Body Weight(g), serum non-fasting Glucose, Cholesterol (Chol), triglyceride (TG), ALT, ALP of the mice at the week6

|                | Control (1) | High fat diet (2) | Sham(3) | Metformin (4) | Cymene (5) | Metformin + Cymene (6) |
|----------------|------------|-------------------|---------|--------------|------------|-----------------------|
| Weight(gr)     | 41 ±.86    | 40.50±.76         | 41.5±1.04| 39.5±1.04    | 40±1.15    | 40.071±.80            |
| Non-fasting Glucose | 273±10.4   | *320±7.64         | *325±11.06| +261±4.58   | +++243±7.02| +273±9.7              |
| Chol           | 135±4.5    | 150±11.3          | 152±11.3| 139±3.7     | 144±±5.5   | 146±9                 |
| TG             | 120±3.6    | 136±7.02          | 147±8.54| +96±7.63    | 129±8.08   | 110±7.02              |
| ALT            | 54±3.71    | 67±4.04           | 60±3.05 | 53±3.06     | +++43±3.05 | +++38±2.51            |
| ALP            | 201±5.85   | 220±5.29          | 210±7.21| 200±8.54    | +++172±9.165| *179±10              |

ALP.Data are shown as mean ± SEM. *\(p < 0.05\) compared with the normal control group, +++\(p < 0.001\) compared with the high fat diet group, ++\(p < 0.01\) compared with the high fat diet group, +\(p < 0.05\) compared with the high fat diet group.

---

![Fig. 1 Trichrome-stained sections of liver from control (a), HFD-given (b), metformin-treated (c), metformin + p-Cymene (d), and p-cymene (e) groups. Magnification is of (400x)](image-url)
levels occurred compared with the HFD group ($p < 0.001$), while treatment with the cymene and metformin combination made a significant difference with the normal control group ($p < 0.05$). ALP levels were also significantly affected by the combinative treatment ($p < 0.05$) and cymene treatment ($p < 0.01$) compared with the HFD group. Metformine alone had no significant effect in this regard.

**Histological analysis**

Histological examination with trichrome staining of liver sections from HFD-fed mice demonstrated the development of steatosis as shown in Fig. 1. The fat droplets were decreased in the groups that had received either metformin or metformin combination with cymene.

**Discussion**

In the present study, the body weight of animals did not change significantly upon treatment with metformin. Typical weight loss reported upon use of metformin is modest [29]. As an example, a weight loss of 3 kg over 16 weeks with metformin and a weight-maintaining diet may be cited [30]. The present study period is also a limitation in this regard. Interestingly, thymol, which is has a similar structure to $p$-cymene has been reported to decrease animals weight which had been treated with a high-fat diet [31].

On the other hand, metformin treatment resulted into significant decrease of blood glucose levels of HFD-treated animals (around 20 %). Metformin is reported to suppress glucose production in the liver and may result to 25–30 % reduction of fasting plasma glucose concentrations [30, 32]. $P$-cymene and its combination with metformin were also effective in this regard, a fact that was observed with thymol too [31]. In this regard, $p$-cymene could have a potentially positive effect in diabetic state, which should be checked in suitable diabetic models.

Lipid profile was influenced by the treatment, although overall not significantly. The only significant effect was obtained by the use of metformin on TG levels. Meta-analyses have shown positive although small effect of metformin on lipid profile factors in diabetic patients [33], while combination of metformin with other noninsulin anti-hyperglycemic drugs was found to be moderate to small [34]. In NAFLD patients, as well as obese non-diabetic patients various results had been obtained, with effectiveness of metformin shown in some cases [35, 36]. In other reports, thymol and carvacrol, which have similarity with cymene in their chemical structures have been shown to be effective on obese animals lipid profiles [31, 35]. With regard to cymene effect, since a decrease is observed in TG and cholesterol levels of treated animals, the hypolipidemic potential of the compound could not be discarded, but further testing with other doses and treatment periods are needed.

Concerning ALT and ALP levels, HFD treated animals showed no significant difference with the control group. Metformin supplementation had also no significant effect on these levels, where cymene caused a significant decrease of ALT and ALP. In reported studies, metformin (1–1.5 g/day) has been effective in reduction of ALT levels [37, 38]. The lack of metformin effect observed in this study may be related to the limited period of the study.

**Conclusions**

Use of the simple compound $p$-cymene has shown a significant effect on blood glucose levels of HFD-treated animals, as well as on ALT and ALP levels. Slight effects were also detected toward lipid profiles which may be indicative of a potential of this compound in this regard. Overall, the effects of cymene were comparable with metformin, and show its potential as an alternative to the latter. Further studies involving longer periods are needed to fully validate these results.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

This manuscript is a report from PL MS.C. thesis, to which PY and AE-H have been advisors. All authors have also contributed to the writing and editing of the manuscript. All authors read and approved the final manuscript.

**Author details**

1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
2. Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Shariati Hospital, North Kargar Avenue, 1411413137 Tehran, Iran.
3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

**Received:** 17 February 2015 **Accepted:** 18 June 2015 **Published online:** 24 June 2015

**References**

1. Schrauwen P, Westerterp KR. The role of high-fat diets and physical activity in the regulation of body weight. Br J Nutr. 2000;84(1):417–27.
2. Klaas S. Increasing the protein/carbohydrate ratio in a high-fat diet delays the development of adiposity and improves glucose homeostasis in mice. J Nutr. 2005;135(8):1854–8.
3. Bray GA, Paeratakul S, Popkin BM. Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav. 2004;83(4):549–55. doi:10.1016/j.physbeh.2004.08.039.
4. Tabatabaei-Malazy D, Hasani-Ranjbar S, Arnoli MM, Heshmat R, Sajadi M, Derakhshan R et al. Gender-specific differences in the association of adiponectin gene polymorphisms with body mass index. Rev Diabet Stud. 2009;6(1):241–6. doi:10.1900/RDS.2010.7.241.
5. Shaw D, Hall W, Williams C. Metabolic syndrome: what is it and what are the implications? Proc Nutr Soc. 2005;64(3):349–57.
6. Shinya T, Tsuchya H. Pathophysiology of NASH: insulin resistance, free fatty acids and oxidative stress. J Clin Biochem Nutr. 2006;38(3):127–32.
7. Rutter MK, Meigs JB, Wilson PW. Cardiovascular risk and the metabolic syndrome. Metab Syndr Relat Disord. 2006;4(4):252–60.
8. Esposito K, Cefalu W, Giugliano D. Diet and the metabolic syndrome. Metab Syndr Relat Disord. 2007(5):291–6.
9. Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med. 1997;3(1):37–48.
10. Mahdad N, Boukortt FO, Benzian Z, Bouchenak M. Lifestyle advice follow-up improve glycemic control, redox and inflammatory status in patients with type 2 diabetes. J Diabetes Metab Disord. 13(1):122. doi:10.1186/s40209-014-0122-1.
11. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg. 2004;14(5):589–600. doi:10.1381/096092004230905453.
12. Bastard J-P, Maachi M, Lagathu C, Kim MJ, Canon M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
13. Dandonna P, Ajalda A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4–7.
14. Esposto K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289(14):1799–804.
15. Charrière G, Cousin B, Arnaud E, André M, Baccou F, Penicaud L, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850–2.
16. Ba C, Munoz O, Andre M, Fonstrlenes A, Dani C, Cousin J. A role for preadipocytes as macrophage-like cells. FASEB J. 1999;13(2):305–12.
17. Zarshenas MM, Samarsi SM, Pentarvà P, Moein M. Analysis of the essential oil components from different Carum copticum L. samples from Iran. Pharmacognosy Res. 2014;6(1):62.
18. Behera GC, Parida K, Das D. Facile fabrication of aluminum-promoted vanadium phosphate: a highly active heterogenous catalyst for isopropylation of toluene to cymene. J Catalysis. 2012;289:190–8.
19. Nabavi SM, Marchese A, Izadi M, Curti V, Daglia M, Nabavi SF. Plants belonging to the genus Thymus as antibacterial agents: from farm to pharmacy. Food Chem. 2015;173:339–47.
20. Nickwar B, Adeli A, Nickwar A. TLC-Bioautography and GC-MS analyses for detection and identification of antioxidant constituents of trachyspermum cuminum essential oil. Iran J Pharm Res: IJPR. 2011;10(1):127.
21. Santana MF, Quintans-Júnior LJ, Cavaletti SC, Oliveira MG, Guimarães AG, Cunha ES, et al. p-Cymene reduces orofacial nociceptive response in mice. Revista Brasileira de Farmacognosia. 2011;21(6):1138–43.
22. Bonjardim LR, Cunha ES, Guimarães AG, Santana MF, Oliveira MG, Seraffin MR, et al. Evaluation of the anti-inflammatory and antinociceptive properties of p-cymene in mice. Zeitschrift für Naturforschung C-J Biosci. 2012;67(1):15.
23. Chen L, Zhao L, Zhang C, Lan Z. Protective effect of p-cymene on preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850–2.
24. Di Pietro M, Parborell F, Irusta G, Pascuali N, Bas D, Silvia Bianchi M, et al. Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes. 2010;59(7):1608–15. doi:10.2337/db09-1679.
25. Wulffele MG, Kocy A, de Zeeuw D, Stenhoveur CD, Garsevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256(1):1–14. doi:10.1111/j.1365-2756.2004.01328.x.
26. Dai X, Wang H, Jing Z, Fu P. The effect of the dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. Curr Med Res Opin. 2014;30(9):1777–86. doi:10.1185/03007995.2014.921608.
27. Fortbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BiPGERO Study Group. Diabetes. 1996;45(9):920–6.
28. Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis. 2004;36(8):406–11.
29. Cho S, Choi Y, Park S, Park T. Carvacrol prevents diet-induced obesity by modulating gene expressions involved in adipogenesis and inflammation in mice fed with high-fat diet. J Nutr Biochem. 2012;23(2):192–201. doi:10.1016/j.jnutbio.2011.01.016.
30. Bugianesi E, Gentilecchio E, Manini R, Natale S, Vanni E, Vilainova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100(3):1082–90.